Neurology Central

Warnings that stopping Gilenya® could make multiple sclerosis worse: industry news round-up

In this week’s industry news round-up we cover the latest headlines on multiple sclerosis, glioblastoma and illegal marketing of dietary supplements containing antidepressants. Find out more about our selection of the highlights below.
Our selection of the highlights includes:

BrainStorm Cell Therapeutics submits IND for NurOwn® in progressive multiple sclerosis

BrainStorm Cell Therapeutics (NY, USA) has announced that it has submitted an Investigational New Drug (IND) application with the US FDA to initiate a Phase II study of NurOwn® in patients with progressive multiple sclerosis (MS).

“We plan to quickly initiate the Phase II clinical study of NurOwn in progressive MS to address the significant unmet need for MS patients,” commented Ralph Kern, Chief Operating Officer and Chief Medical Officer of BrainStorm. “We believe the demonstrated safety and efficacy experience of NurOwn in our amyotrophic lateral sclerosis clinical program and development of neurotrophic factors and other efficacy biomarkers will allow us to confidently expand our cellular therapy pipeline.”

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.